Why the Creso Pharma (ASX:CPH) share price fell 9% before freezing

Creso Pharma shares came to a halt this afternoon, here's what is happening…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Creso Pharma Ltd (ASX: CPH) share price came under pressure this afternoon. This followed breaking news published by The Australian Financial Review involving the cannabis and psychedelics company's non-executive chair, Adam Blumenthal.

Shares in the small-cap company tumbled 9% to 12.3 cents apiece before being placed into a trading halt. The frozen share price will remain in place until Creso can respond to the ASX's price query.

However, the intriguing news today relates to the office raid of Mr Blumenthal.

A dollar sign embedded in ice, indicating a share price freeze or trading halt

Image source: Getty Images

Creso Pharma share price falls amid ASIC investigation at EverBlu

Investors weren't playing around this afternoon after they got word of what was going on in Sydney today. It appears shareholders were quite nervous about the news that Creso Pharma's non-exec chair, Blumenthal, had his office raided by the Australian Federal Police (AFP) today.

To be clear, the office raided was not that of Creso Pharma. Rather, it was Blumenthal's boutique corporate advisory company, EverBlu Capital.

According to reports, officers were adorning gloves and flicking through files to assist the Australian Securities and Exchange Commission (ASIC) with an investigation. Neither the AFP nor ASIC have shed any further light on exactly what the investigation is in relation to.

The EverBlue Capital team was involved in advising Creso Pharma on its bonus options issue in October. My colleague, Zach, covered this at the time, outlining how the financial instrument could be used to raise capital if exercised.

Talk about timing

As fate would have it, the precarious situation has come to light mere days after Creso Pharma handed down its trading update for Q4 FY21. Overall, the update was reasonably positive for the company, pushing The Creso Pharma share price higher.

Furthermore, the quarter saw the company achieve strong revenue growth in its Swiss operations. However, the market's sentiment might now be tainted by the latest developments involving Adam Blumenthal.

The Creso Pharma share price will remain halted until an announcement is provided, or until the commencement of trade on Thursday, 18 November 2021.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Falling pills in a blue background.
Healthcare Shares

This ASX healthcare company's profit has rocketed 24%

Expansion into new markets is paying off.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Are these rocketing ASX healthcare shares a must buy?

These companies all rose significantly to start the week.

Read more »

A doctor and an elderly couple sit at a desk and look at a lung scan uploaded.
Healthcare Shares

Why did 4DMedical shares charge higher today, then drop?

The company's key technology has received a big tick.

Read more »

Business woman working from home with stock market chart showing percent change on her laptop screen.
Healthcare Shares

Should I invest $10,000 in CSL shares before the end of May?

This ASX healthcare giant has fallen hard, but the lower price and improving dividend appeal make it worth another look.

Read more »

A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
Healthcare Shares

Why this fallen ASX 200 blue chip could be a strong buy

I think the market may be underestimating the durability of this healthcare business.

Read more »

Female pharmacist smiles with a digital tablet.
Broker Notes

3 reasons to buy Sigma Healthcare shares today

A leading analyst expects “impressive growth” from Sigma Healthcare shares.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news.
Healthcare Shares

Could this fallen ASX 200 stock be a once-in-a-decade opportunity?

The valuation now looks far more interesting for a healthcare stock with a global leadership position.

Read more »

Hand dropping a mic.
Healthcare Shares

Pro Medicus shares jump as massive US contract win turns heads

Pro Medicus shares are rocketing after a major US win.

Read more »